Home/Kyverna Therapeutics/Dominik Rüttinger
DR

Dominik Rüttinger

Chief Medical Officer

Kyverna Therapeutics

Kyverna Therapeutics Pipeline

DrugIndicationPhase
KYV-101 (mivocabtagene autoleucel)Lupus NephritisPhase 2
KYV-102Autoimmune DiseasesPhase 1
KYV-201Autoimmune DiseasesPreclinical